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Background: The pathophysiologic mechanisms classically involved in sickle-cell nephropathy include endothelial
dysfunction and vascular occlusion. Arguments demonstrating that ischemia-reperfusion injury-related kidney
damage might coincide with vaso-occlusive crisis (VOC) are lacking.
Methods: In this prospective study, we sought to determine whether tubular cells and glomerular permeability might
be altered during VOC. Urine neutrophil gelatinase-associated lipocalin (NGAL) levels and albumin-excretion rates (AER)
of 25 patients were evaluated prospectively during 25 VOC episodes and compared to their steady state (ST) values.
Results: During VOC, white blood-cell counts (WBC) and C-reactive protein (CRP) were significantly higher than at ST
but creatinine levels were comparable. Urine NGAL levels were significantly increased during VOC vs ST (P = 0.007) and
remained significant when normalized to urine creatinine (P = 0.004), while AER did not change significantly. The higher
urine NGAL concentration was not associated with subsequent (24-48 hour) acute kidney injury. Univariate analysis
identified no significant correlations between urine NGAL levels and laboratory parameters during VOC.
Conclusions: These results demonstrated that subclinical ischemia-reperfusion tubular injury is common during VOC
and highlight the importance of hydroelectrolyte monitoring and correction during VOC.Background
Sickle-cell nephropathy (SCN), a major mortality risk
factor in sickle-cell disease (SCD) patients, is characterized
by early increased glomerular filtration rates (GFR),
frequently associated with proteinuria, that promote
progressive renal function decline [1-3]. Although the
SCN pathophysiologic process remains hypothetical,
chronic hemolysis-related endothelial dysfunction and the
relative renal hypoxia triggered by repeated vaso-occlusive
crises (VOC) are currently considered critical key factors
[2,4,5]. Experimental data from murine SCD models
demonstrated that ischemia-reperfusion (I-R) injury can
induce direct kidney damage, characterized by marked* Correspondence: vincent.audard@hmn.aphp.fr; pablo.bartolucci@hmn.aphp.fr
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unless otherwise stated.renal vascular congestion and tubular injury, associated
with renal hemodynamic changes [6,7]. In SCD patients,
VOC initiation, progression and resolution may be
considered typical features of I-R injury [8,9], but
definitive proof of I-R–induced tubular injury in SCD
patients during VOC is lacking. Renal tubular cells,
a predominant site of cell metabolic activity and
oxygen consumption, are highly susceptible to oxygen
deprivation during I-R injury [10]. However, clinical
demonstration that the kidneys are a major I-R site
during SCD VOC remains unsubstantiated. We com-
pared prospective urine neutrophil gelatinase-associated
lipocalin (NGAL), a tubular injury biomarker [11], and
albumin-excretion rate (AER) levels during VOC to steady
state (ST) values to determine whether renal tubular
cells and glomerular capillary permeability could be
directly affected during VOC.
Methods
This prospective study, approved by our local Ethics
Committee, was conducted in our Adult Sickle-CellLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Comparisons of biologic parameters during 25
patients’ sickle-cell disease vaso-occlusive crises (VOC)
and at steady state (ST)
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Helsinki, Good Clinical Practice guidelines, and local
laws and regulations. Patients were enrolled after giving
their written informed consent.
Homozygous SCD patients, at least 18 years old with
severe VOC requiring hospitalization for pain (regardless
of location) not controlled by grade-II analgesics, were
eligible for inclusion once. VOC was defined as pain or
tenderness requiring opioids and not attributable to
other causes [12]. Exclusion criteria included: VOC with
parenteral hydration lasting >24 hours; blood transfusion
during the previous month; acute chest syndrome or
severe complication requiring blood transfusion at
inclusion; pregnancy and/or psychiatric disorder; pre-
existing renal insufficiency, defined as GFR ≤60 mL/min/
1.73 m2 according to the modification of diet in renal
disease (MDRD) formula, and/or Hydroxyurea use when
the VOC occurred or at ST.
Standardized clinical practices included bed rest, fluid
replacement with 5% glucose (2 L with NaCl 4 g/L), oral
alkaline water (500 mL/day), folinic acid (5 mg/day),
analgesia with morphine and intravenous paracetamol
(1 g every 6 hours), and preventive incitative spirometry.
Urine NGAL levels and biological parameters were
determined simultaneously on samples collected on D1,
D2 or D4 of hospitalization for each of the 25 patients’
single VOC and at an ST consultation. ST was defined
as a consultation ≥1 months after a VOC and ≥3 months
after blood transfusion. The Acute Kidney-Injury Network
(AKIN) criteria stratify AKI into 3 stages reflecting
severity of the percentage serum-creatinine change
[measured using the Jaffe kinetic method (Gen.2, Roche
Diagnostics, France)] [13]. All room-temperature urine
samples were centrifuged (2000 g × 5 minutes) within
2 hours of arriving at the lab and frozen at -80°C until
assayed. An enzyme-linked immunosorbent assay kit
(BioPorto Diagnostics A/S, Denmark) determined NGAL
levels according to the manufacturer’s instructions. AER
of <3, 3-30 or >30 mg/mmol creatinine defined normal,
micro- or macroalbuminuria, respectively.Parameter VOC ST P value
Hemoglobin (g/dL) 8.3 ± 1.3 8.8 ± 1.2 0.01
White blood-cell count (106/L) 12216 ± 4599 9832 ± 3359 0.009
Lactate dehydrogenase (IU/L) 434.8 ± 181.5 392.5 ± 213.1 0.16
Creatinine (μmol/L) 60.3 ± 16.8 57.5 ± 16.1 0.24
Urea (mmol/L) 2.2 ± 1.1 2.9 ± 1.1 0.01
Albuminuria (mg/L) 71.1 ± 259.4 139.4 ± 347.0 0.14
Albuminuria/creatinuria
(mg/mmol)
14.6 ± 47.5 18.4 ± 46.9 0.38Statistical analyses
Results are expressed as means ± standard deviation or
numbers (%). Between-group quantitative parameters
were compared with paired Student t-tests. Simple linear
regressions were computed for each biologic parameter to
search for potential relationships with NGAL. Spearman’s
correlation coefficient established correlations; P < 0.05
defined significance.Urine NGAL (ng/mL) 76.7 ± 76.7 28.7 ± 25.7 0.007
NGAL/creatinuria (mg/mmol) 17.1 ± 20.7 3.9 ± 3.6 0.004
C-Reactive protein (mg/L) 54.9 ± 60.5 9.1 ± 7.2 0.003
Values are means ± standard deviation.Results and discussion
Twenty-five SS SCD patients (12 men, 13 women; mean
age: 34.6 ± 6 years), each hospitalized for a VOC, wereincluded. The mean VOC-onset-to-hospitalization interval
was 30.4 ± 23.1 hours. The mean pain visual analog scale
at inclusion was 7.2 ± 1.3. None had received nonsteroidal
anti-inflammatory drugs (NSAID) to treat VOC. Mean
systolic and diastolic blood pressures during VOC were,
respectively, 115 ± 13 and 71 ± 9 mm Hg. During
VOC, white blood-cell counts (WBC) and C-reactive
protein (CRP) were significantly higher than at ST but
creatinine levels were comparable (Table 1). During
hospitalization, no infection was documented and no
patient had AKI satisfying AKIN criteria. The latter obser-
vation confirms our reported finding that AKI is rare
during VOC [14]. Notably, AKI absence did not ex-
clude possible VOC association with subclinical renal
I-R injury.
We next analyzed AER and urine NGAL level changes
between VOC and ST. AER, an early marker of renal
damage, reflects glomerular endothelial dysfunction and
impaired glomerular barrier permeability [15]. It was
reportedly elevated in 68% of adult SCD patients [1]. At
ST, 15 (60%), 7 (28%) or 3 (12%) patients, respectively,
had normal, micro- or macroalbuminuria. VOC and ST
AER were comparable (Table 1), suggesting that, during
VOC, I-R injury does not directly target glomerular
permeability. NGAL, an extracellular, 25-kDa protein, is
expressed at low levels in several human tissues, eg
kidney [16], and is induced in tubular cells early after
renal ischemic injury [17]. Urine or serum NGAL levels
are considered relevant biomarkers of AKI [16,18].
Patients with preexisting renal insufficiency were excluded
from our analysis because recent findings suggested that
urine and serum NGAL concentrations increased in
parallel with renal disease severity [19]. Moreover,
NSAID, known to cause tubular injury, were not used
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showed limited ketoprofen impact on VOC requiring
hospitalization [12]. Sundaram et al recently demonstrated
that ST urine NGAL levels were subnormal in 116
SCD patients and independent of the degree of albumin-
uria [20]. Herein, urine NGAL levels increased signifi-
cantly during VOC (P = 0.007) and remained significant
when normalized to urine creatinine (P = 0.004) (Figure 1).
NGAL concentrations on hospital D1, D2 or D4 (n = 9,
11 and 5, respectively) were comparable (P = 0.9). Median
urine NGAL values were significantly associated
with AKI stage in a cohort of patients without AKI
or with stage-3 AKIN admitted to the emergency
department (respectively, 23 vs 153 ng/mL) [21]. Our
patients’ mean NGAL-level increase in urine samples
collected a mean of 30.4 ± 23.1 hours after VOC onset
was relatively weak (76.7 ng/mL), probably reflecting
subclinical renal injury, because none had AKI meeting










































Figure 1 Urine NGAL levels (A) and urine NGAL/creatinine ratios
(B) in 25 SCD patients at vaso-occlusive crises (VOC) and steady
state (ST).Based on the 50 samples from 25 patients, no
correlation was found between urine NGAL levels
and other laboratory parameters considered (WBC
counts, hemoglobin, CRP, lactate dehydrogenase, ASAT,
bilirubinemia and creatinine levels). These findings
suggest that acute tubular injury during VOC is not
directly related to hemolysis, anemia and inflamma-
tory syndrome that may confound NGAL level inter-
pretation in these patients [16]. Furthermore, they
highlight the importance of correcting hydroelectro-
lyte disturbances, particularly acidosis, which raises
the hemoglobin desaturation rate and favors HbS
polymerization. Indeed, our therapeutic protocol for
VOC includes bicarbonate administration. The first
objective of our study was not to determine whether
a potential increase of urine NGAL levels might be
predictive of subsequent acute kidney injury (AKI) in
these patients, as we previously demonstrated that
AKI during VOC is a rare finding [14]. Our study’s
primary aim was to determine whether increased
urine NGAL levels might represent a pertinent bio-
marker attesting to subclinical tubular impairment
in these patients. In agreement with that hypothesis,
as observed herein, Haase et al recently identified,
among 2322 critically ill patients, 19.2% failing to
meet current creatinine-based consensus criteria for
AKI but probably having acute tubular injury, based
on increased NGAL levels [22]. We postulate that
repeated tubular injury in the context of multiple
VOC might promote hypoxic stress, thereby inducing
a chronic inflammatory state in renal parenchyma,
leading to progressive tubulointerstitial and glomeru-
lar damage [4,23].
Conclusions
This study is the first to indicate that I-R tubular damage
might occur simultaneously with VOC, as revealed by
increased urine NGAL levels. The demonstration that
tubular cells are indeed a major site of tissue-oxygen
deprivation during SCD VOC is important for VOC
management and emphasizes the need to improve
intravenous hydration and patients’ tissue oxygenation
during VOC. Further investigations are needed to evaluate
a potential direct relationship between elevated NGAL
levels during VOC and the risk of subsequent chronic
kidney disease.
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